Trial Profile
A double-blind, placebo controlled, phase I study to assess safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of GIC-1001 in normal healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trimebutine 3-thiocarbamoylbenzenesulfonate (Primary)
- Indications Procedural pain
- Focus Adverse reactions
- Sponsors gIcare Pharma
- 22 Mar 2014 Multiple ascending dose results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 22 Mar 2014 Single ascending dose results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 08 Mar 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.